UNSPSC 51142554: Lisuride maleate

This classification denotes an antiparkinsonian agent with the molecular formula C20H26N4O.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UV1635N8XW, chemically known as 3-(9,10-didehydro-6-methylergolin-8alpha-yl)-1,1-diethylurea but more generally known as lisuride maleate, which bears US NIH Compound Identifier 28864. European Medicines Agency schedules Lisuride maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02940MIG.

Most nations, for tariff and trade purposes, schedule lisuride maleate under HS 29396900 and SITC 54146. As of Q4 2014, LISURIDE MALEATE remains US FDA's Preferred Term for this commodity. SMILES: CCN(CC)C(=O)N[C@@H]1CN([C@@H]2CC3C[NH]C4C3C(CCC4)C2=C1)C.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51142554 Lisuride maleate is a Commodity code that shows minimal alignment with recent state and local procurement activity. The single recorded opportunity under this code — Seminole County, Florida's IFB 60459723LAS — solicits naloxone and drug deactivation systems for community health support, which falls outside the scope of lisuride maleate, a dopamine agonist pharmaceutical used in neurological treatment. The mismatch suggests either a cataloging error in the state system or that lisuride maleate itself does not drive meaningful procurement volume in state and local markets at present.

Seminole County's naloxone procurement on June 30, 2026 (with response deadline July 26, 2023) represents the only recent documented opportunity; the county sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Vendors were required to submit electronic bids including all shipping and delivery costs, maintain workers' compensation and liability insurance, and pass E-Verify compliance checks. The contract carried a two-year initial term with one-year renewal option and a three-month probationary period. No other issuing bodies or geographic concentrations emerge from available records, and no opportunities specifically targeting lisuride maleate appear in recent state or local solicitation activity.